Results 61 to 70 of about 648 (164)

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA

Neurology and Therapy
Introduction Multiple sclerosis (MS) is a heterogeneous disease affecting a diverse population. Compared with white people with MS (PwMS), Black PwMS have more severe disease and higher incidence of MS, whereas Hispanic PwMS experience earlier onset ...
Sophia Woodson, Edward J. Gettings, Chu-Yueh Guo, Sylvia Klineova, Jong-Mi Lee, Rebecca S. Romero, Aljoeson Walker, Kinyee Fong, Jason P. Mendoza, Nicholas Belviso, Boyang Bian, James B. Lewin, Sai L. Shankar   +12 more
doaj   +1 more source

Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019 [PDF]

, 2022
Purpose: Multiple sclerosis (MS) is a chronic disease of the central nervous system that disproportionately affects women, with typical onset during reproductive age. Several disease-modifying therapies (DMTs) are FDA-approved to slow disease progression,
Duchesneau, E.D., Jonsson Funk, M., Kinlaw, A.C., Lund, J.L., Pate, V.   +4 more
core   +2 more sources

Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists

European Journal of Neurology, Volume 32, Issue 4, April 2025.
ABSTRACT Background Multiple sclerosis (MS) places substantial socioeconomic burden on patients due to its early onset and progressive nature, but healthcare systems are also impacted by the high costs of disease‐modifying treatments (DMTs). The use of generics (for conventional drugs), biosimilars (for biologics) or follow‐on versions of non‐biologic ...
Thomas Berger, Markus Zeitlinger, Veronica Popescu, Melinda Magyari, Laura Airas, Mona Alkhawajah, Maura Pugliatti, Magd Zakaria, Carlo Pozzilli, Jelena Drulovic, Bart Van Wijmeersch, Patrick Vermersch, Celia Oreja‐Guevara   +12 more
wiley   +1 more source

Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors

Annals of Clinical and Translational Neurology, Volume 12, Issue 3, Page 643-647, March 2025.
Abstract This study evaluated disease activity in people with Multiple Sclerosis (PwMS) who received immune checkpoint inhibitors (ICIs) compared to PwMS not treated with ICIs. There were 108 PwMS included (27 PwMS+ICIs and 81 PwMS controls), matched on age, sex, disease duration, DMTs, and MS disease course. Of 27 PwMS+ICIs, one (4%) had a relapse and
Saira Afzal, Yadi Li, Brittany Lapin, Le H. Hua, Lucy Boyce Kennedy, Wen Wee Ma, Marisa McGinley, Jeffrey A. Cohen, Amy Kunchok   +8 more
wiley   +1 more source

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry. [PDF]

, 2020
BACKGROUND: Nine oral disease-modifying therapies (DMTs) have been approved for the treatment of multiple sclerosis (MS) in the United States. Few studies have examined self-reported quality of life (QoL) and functional status outcomes among patients who
Baraban, Elizabeth, Chen, Chiayi, Cohan, Stanley, Hashemi, Lobat, Lucas, Lindsay, Smith, Alden, Spinelli, Kateri, Stuchiner, Tamela   +7 more
core   +1 more source

Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy [PDF]

, 2021
Imbalances in redox homeostasis can result in oxidative stress, which is implicated in various pathological conditions including the fatal neuromuscular disease Duchenne Muscular Dystrophy (DMD).
de Haan, Judy B, Fischer, Dirk, Gueven, Nuri, Kourakis, Stephanie, Rybalka, Emma, Timpani, Cara   +5 more
core   +3 more sources

Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis

Annals of Clinical and Translational Neurology, Volume 12, Issue 3, Page 615-630, March 2025.
This study aimed to assess gray matter (GM) atrophy, the contribution of white matter (WM) lesions, and consequent structural disconnectivity in minority patients with multiple sclerosis (PwMS). Minority PwMS were found to have greater lesion burden and GM atrophy. Differences in GM atrophy were partially mediated by WM pathology. Abstract Objective To
Ahmed Bayoumi, Joseph A. Thomas, Breanna R. Alonzo, Juan Jimenez, Christopher M. Orlando, Carlos A. Pérez, Khader M. Hasan, Jerry S. Wolinsky, John A. Lincoln   +8 more
wiley   +1 more source

De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study

European Journal of Neurology, Volume 32, Issue 2, February 2025.
ABSTRACT Background and Objective High‐efficacy (HE) disease‐modifying therapies (DMT) are increasingly used to treat multiple sclerosis (MS). Concerns arise when considering the decreasing efficacy and increasing risk of adverse events in aging patients.
Frederik Elberling, Mie Reith Mahler, Luigi Pontieri, Finn Sellebjerg, Melinda Magyari, for the DMSG Study Group   +5 more
wiley   +1 more source

Exploring the dual role of fumarate as an intracellular and extracellular hypoxia-induced signalling molecule [PDF]

Myocardial ischemia is characterised by a restriction in blood flow to the heart, which limits nutrient and oxygen supply and removal of waste products. In healthy hearts, ischemia triggers a cardiac metabolic shift from oxidative metabolism to anaerobic
Castro Guarda, Marcos Felipe
core   +2 more sources

Subclinical imaging activity in multiple sclerosis patients during war‐related psychological stress

Annals of Clinical and Translational Neurology, Volume 12, Issue 1, Page 17-25, January 2025.
Abstract Objectives Psychological stress has been suggested as a contributory factor in the onset and progression of multiple sclerosis (MS). The 7 October 2023 terrorist attacks in Israel caused significant psychological stress, providing a unique context to study its impact on MS activity.
Omri Zveik, Tal Friedman‐Korn, Ariel Rechtman, Tal Ganz, Garrick Hoichman, Lyne Shweiki, Dana Ekstein, Adi Vaknin‐Dembinsky   +7 more
wiley   +1 more source